Effect of Schisandrin B on Proliferation and Migration of Human SW620 Colon Cancer Cell Via VEGF/PI3K/Akt Signaling Pathway
DAI Guo-liang1, GONG Tao2, LI Yu1, DING Kang2, WU Kun-lan2, LI Zhi-wei3, JU Wen-zheng1, ZHANG Jun1*
1. Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China; 2. The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210001, China; 3. School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
Abstract��OBJECTIVE To study the changes of VEGF signaling pathway in colon cancer patients and the effect of schisandrin B on SW620 cells and to analyze its possible mechanism. METHODS The protein expression of VEGFA, VEGF-R2, PI3K, Akt and p-Akt in human cancerous colon samples and adjacent normal samples were detected by Western blotting. The proliferation of SW620 cells was detected by CCK-8 method. The mRNA expression of VEGFA, VEGF-R2, PI3K and Akt in SW620 cells were detected by real-time PCR. The protein expression of VEGFA, VEGF-R2, PI3K, Akt and p-Akt in SW620 cells were detected by Western blotting. RESULTS The protein expression of VEGF-R2, PI3K, Akt and p-Akt in human cancerous colon samples was significantly higher than that in the adjacent normal samples(P<0.05). Compared with the control group, schisandrin B could significantly inhibit the proliferation and migration of SW620 cells, the mRNA expression of VEGFA, VEGF-R2, PI3K and Akt(P<0.01) and the protein expression of VEGFA, VEGF-R2, PI3K, Akt and p-Akt(P<0.05) in SW620 cells also were significantly decreased by schisandrin B. CONCLUSION The VEGF/PI3K/Akt signaling pathway is activated in colon cancer patients. Schisandrin B could inhibit the activity and migration of SW620 cells and inhibit the VEGF/PI3K/Akt signaling pathway.
������,����,��ԥ,����,�⍋�,����ޱ,������,�ž�. ��ζ������ͨ��VEGF/PI3K/Akt�ź�ͨ·�����˽᳦��ϸ��SW620����ֳ��Ǩ��[J]. �й�ҩѧ��־, 2018, 53(14): 1186-1191.
DAI Guo-liang, GONG Tao, LI Yu, DING Kang, WU Kun-lan, LI Zhi-wei, JU Wen-zheng, ZHANG Jun. Effect of Schisandrin B on Proliferation and Migration of Human SW620 Colon Cancer Cell Via VEGF/PI3K/Akt Signaling Pathway. Chinese Pharmaceutical Journal, 2018, 53(14): 1186-1191.
WHO. Globocan 2012:Estimated Cancer Incidence. Mortality and prevalence worldwide in 2012[EB/OL]. WHO, 2012, http://globocan.jarc.fr/Defauit.aspx.
[2]
PAN Y, LIN J X, LI Y. Research on pharmacological action of schisandrin B[J]. J Jilin Med Coll(����ҽҩѧԺѧ��), 2015, 36(1):60-62.
[3]
HUANG X R, QI M X, YE H Z, et al. An experimental study on protection of schisandrin B against oxidative damages of lens in vitro[J]. Chin Pharm J (�й�ҩѧ��־), 2001, 36(5):310-313.
[4]
WU X H, HOU X J, XU X N, et al. The antitumor multi-mechanism of schisandrin[J]. J Jilin Med Col(����ҽҩѧԺѧ��), 2012, 33(2):107-110.
[5]
LIANG J, HOU H Y, LAN X X, et al. Advance in study on pharmacological effect and molecular mechanisms of schisandrin B[J]. Chin J Mod Appl Pharm(�й��ִ�Ӧ��ҩѧ), 2014, 31(4):506-510.
[6]
JEMAL A, SIGEL R, XU J, et al. Cancer statistics[J]. CA Cancer J Clin, 2010, 60(5):277-300.
[7]
SHI J F, YAN C. Studing on the mechanism of action in schisandra B to anti-hepatoma in the rats[J]. Chin J Mod Drug Appl(�й��ִ�ҩ��Ӧ��), 2012, 6(23):1-2.
[8]
LIU X Y, WANG L B, HOU X J, et al. The effect of schisandrin B inhibiting the growth of glioma in vivo[J]. Chin J Gerontol(�й�����ѧ��־), 2011, 33(17):4176-4177.
[9]
LIU Z. Schisandrin B suppresses invasion and metastasis of breast cancer in vivo and in vitro by epithelial-mesenchymal transition inhibition[D]. Zhejiang University, 2011.
[10]
JIANG E P, LI H, YU C Y, et al. Influence of schisandrin B in apoptosis and invasion of SW480 cells via p38MAPK signaling pathway[J]. J Jilin Univ(���ִ�ѧѧ��), 2015, 41(4):675-679,885.
[11]
CARMELIET P. VEGF as a key mediator of angiogenesis in cancer[J]. Oncology, 2005, 69(3):4-10.
[12]
NAPOLEONE F. VEGF and the quest for tumour angiogenesis factors[J]. Nat Rev Cancer, 2002, 2(10):795-803.
[13]
YANG J. The research of a novel VEGF-target antibody and the molecular mechanisms underlying VEGF-induced tumor progression[D]. Beijing: Academy of Military Medical Sciences, 2014.
[14]
XU W, HUANG J J, CHEUNG P C. Extract of pleurotus pulmonarius sup-presses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway[J]. PLoS One, 2012, 7(3):e34406.
[15]
RUAN G X, KAZLAUSKAS A. VEGF-A engages at least three tyrosine kinases to activate PI3K /Akt[J]. Cell Cycle, 2012, 11(11):2047-2048.
[16]
SKINNER H D, ZHENG J Z, FANG J, et al. Vascular endothelial growth factor transcription alactivation is mediated by hypoxia-inducible factor1a, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling[J]. J Biol Chem, 2004, 279(44):45643-45651.
[17]
LIU P, CHENG H, ROBERTS T M, et al. Targeting the phosphoinositide 3-kinase pathway in cancer[J]. Nat Rev Drug Discov, 2009, 8(8):627-644.
2018, Vol. 53 
